Irfan Asangani

The Asangani Lab at the University of Pennsylvania; we study Transcriptional Addiction in Cancer.

[Irfan Asangani @AsanganiLab]

Asangani Lab is funded again by DoD. This time DoD Idea Expansion award to study the PP2A-AR axis in refractory prostate cancer. 😀

[Univ. of Pennsylvania Department of Cancer Biology @Penn_CBIO]

The University of Pennsylvania @PennMedicine Department of Cancer Biology @Penn_CBIO seeks MD and/or PhD candidates for multiple tenure track positions at the Assistant Professor level. Applicants with expertise in any specific area of CBIO are encouraged. https://t.co/DsGhtFDQ7n

[Penn Epigenetics @PennEpiInst]

The @AsanganiLab is looking for a postdoc in Cancer Epigenomics and Transcriptional Addiction - learn more about the position at the link below and come join a great team! https://t.co/Z6TGtzUtGe

[Neil deGrasse Tyson @neiltyson]

If you are refusing to get vaccinated against COVID-19, maybe it's because you are getting your medical advice from news pundits, fearmongers, conspiracy theorists, and other deeply misinformed people, rather than from Medical Professionals.

[CellCentric @CellCentric]

Many thanks to @AsanganiLab @CD_AACR View: p300/CBP inhibition, CCS1477. A novel therapeutic approach for AR-addicted advanced prostate cancer. https://t.co/YNUG3TdRhW

[Irfan Asangani @AsanganiLab]

Our COVID-19 paper is out in iScience (Cell Press). Extremely proud of first authors @deng_qu @Reyazrasool and Ram Natesan for their contribution to this critical pandemic-related work. #COVID19 #ACE2 #TMPRSS2 @PennMedicine @PennEpiInst @PCFnews

https://t.co/6A3o2LJhr6

[Irfan Asangani @AsanganiLab]

Excited to share our new study on Ewing Sarcoma (EwS). Here we discover stereociliary protein LOXHD1 as a novel oncogene and a potential tumor antigen in EwS.
https://t.co/yM00pWoASK
#sarcoma #immunotherapy #enhancer @GrunewaldLab @deng_qu @biorxivpreprint

[Alumkal Lab @AlumkalJoshi]

Just learned we received funding from @theNCI #BeauBidenCancerMoonshot to study lineage plasticity in prostate cancer! Looking for talented post-docs to drive this project @UMRogelCancer! Please apply and re-tweet! @PCF_Science @UrologySBUR @AmerUrological @UmichCancBio @UMich

[Ekta Khurana @ekta_khurana]

Very excited to share our results about novel subtypes of metastatic castration-resistant prostate cancer ! Led by the awesome @FanyingTang. A true collaboration between @WeillCornell & @sloan_kettering and special thanks to Yu Chen ! https://t.co/I4p5xZmZHe

[Irfan Asangani @AsanganiLab]

@bushraiitk @ConcernFdn @PennEpiInst Thanks.

[CONCERN FOUNDATION @ConcernFdn]

Congratulations to Dr. Irfan Asangani, PhD @AsanganiLab of University of Pennsylvania @PennEpiInst a recipient of our 2020-2022 Conquer Cancer Now Award #grant for their #CancerResearch project in #ProstateCancer
#Immunology https://t.co/yPSST0Pj85
Or TEXT CONCERN to 77948

[Irfan Asangani @AsanganiLab]

@ConcernFdn @PennEpiInst Thank you so much @ConcernFdn for selecting our proposal for a #ConquerCancerNow award! We are grateful for this honor.

[Irfan Asangani @AsanganiLab]

Repurposing Cancer Drugs for COVID-19 https://t.co/HTihtpMFFV

[Irfan Asangani @AsanganiLab]

Excited to share our new story on COVID-19. Our results have implications for understanding male bias in COVID-19 severity and mortality, and provide a strong rationale for androgen deprivation or anti-androgen therapy in men with SARS-CoV-2 infection.
https://t.co/5QNecSLVpE

[Jie Chen @JieChen_Z]

Excited to share our story "Cell Cycle Checkpoints Cooperate to Suppress DNA and RNA-Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses". Really a team effort to make it happen @RogerRogergr @brokendna Big thanks to our collaborators @andyjminn @AsanganiLab

[Irfan Asangani @AsanganiLab]

@VikramParalkar @DrNateW Congrats, Vikram!

[Bushra Ateeq @bushraiitk]

Our paper is out, finally. Congratulations to first authors, @ritika0107 & @ManzarNishat, coauthors, collaborators @NallasivamPala4 @mishabeltran @AminaZoubeidi @FKhaniPath. Thanks to @India_Alliance for funding. Thanks @DBTIndia @serbonline @IITKanpur
https://t.co/bsjQu4sSS6

[Prostate Cancer @CaP_pubs]

Epigenetic Regulation of Chromatin in Prostate Cancer. 𝘼𝙙𝙫 𝙀𝙭𝙥 𝙈𝙚𝙙 𝘽𝙞𝙤𝙡.
https://t.co/1dTzgByXEq

#ProstateCancer @AsanganiLab
https://t.co/5CsMJnQKsU

[Daniel E. Frigo, Ph.D. @DanielFrigo]

Our chapter on PCa #metabolism. Part of a new book-"Prostate Cancer--Cellular & Genetic Mechanisms of Disease Development and Progression" edited by @scottdehm +Don Tindall.

Other great contributions from @AminaZoubeidi @drleighellis @DrSpratticus @quimmateo @AsanganiLab +more

[Liling Wan @LilingWanLab]

excited to see our paper @nature today! We showed how gain-of-function mutations in chromatin reader ENL work to drive Wilms tumor. Fantastic collaborations with many great colleagues in Allis Wen @TjianDarzacq Roeder @Muirlab @KentsisResearch Li labs!
https://t.co/Y2UuLHDiFz